SPOTLIGHT: Novartis touts mid-stage results for MS drug

Novartis said that a mid-stage trial of an oral multiple sclerosis drug demonstrated sustained benefits and good tolerability in patients. The results will clear the way for discussions with the FDA for a Phase III trial to begin next year. Story